Search Orphan Drug Designations and Approvals
-
Generic Name: | raxibacumab | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Trade Name: | ABthraxTM | ||||||||||||||||
Date Designated: | 11/12/2003 | ||||||||||||||||
Orphan Designation: | Treatment of anthrax | ||||||||||||||||
Orphan Designation Status: | Designated/Approved | ||||||||||||||||
Sponsor: |
Human Genome Sciences, Inc. 14200 Shady Grove Road Rockville, Maryland 20850 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
||||||||||||||||
Marketing approved: |
|||||||||||||||||
1 | Generic Name: | raxibacumab |
---|---|---|
Trade Name: | ABthraxTM | |
Marketing Approval Date: | 12/14/2012 | |
Approved Labeled Indication: | Treatment of inhalation anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs, | |
Exclusivity End Date: | 12/14/2019 | |
Exclusivity Protected Indication* : | ||
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-